Gangwe Anil Babanrao, Ekumankama Chibuzo B, Singh Abhishek, Parchand Swapnil Madhukar, Agrawal Deepshikha, Azad Raj Vardhan
Vitreoretina Services, MGM Eye Institute, Raipur, Chhattisgarh, India.
Cornea and Anterior Segment Services, MGM Eye Institute, Raipur, Chhattisgarh, India.
Indian J Ophthalmol. 2025 Jan 1;73(Suppl 1):S119-S125. doi: 10.4103/IJO.IJO_161_24. Epub 2024 Sep 10.
To compare the incidence, type, interval for reactivation, and structural outcomes in infants with aggressive retinopathy of prematurity (A-ROP) treated with ranibizumab or bevacizumab.
It is a single-center, retrospective, consecutive, case series. We included infants with A-ROP which were initially treated with either intravitreal ranibizumab (IVR, 0.25 mg) or intravitreal bevacizumab (IVB, 0.625 mg) between January 2017 and December 2023. The infants were followed up for reactivation. The demographic and clinical data were collected. The time, zone, type of reactivation, its treatment, type of final structural outcome, and factors associated with reactivation were analyzed.
One hundred eight among the 322 infants with A-ROP were included in the study. Fifty-five received IVR, while 53 received IVB. Infants treated with IVR had higher incidence of reactivation (92.7% vs 52.8%, P < 0.001) at an earlier interval than IVB (7.7 weeks vs 12.8 weeks, P < 0.001). Infants treated with IVR had approximately 3.3 times higher possibility of reactivation than those treated with IVB. Three infants (5.9%) in the IVR group and five (9.4%) in the IVB group attained complete vascularization of the retina ( P = 0.72). More infants treated with IVB had regression with a persistent avascular retina (PAR) than IVR (52.8% vs 15.7%, P < 0.001). Infants in the IVB group had 10 times higher possibility of regression with PAR.
Infants of A-ROP treated with IVR have a higher incidence and earlier reactivation, while those treated with IVB have less incidence and delayed reactivation, albeit with a higher possibility of regression with a PAR.
比较雷珠单抗或贝伐单抗治疗的侵袭性早产儿视网膜病变（A-ROP）婴儿的复发率、类型、复发间隔及结构转归。
这是一项单中心、回顾性、连续性病例系列研究。纳入2017年1月至2023年12月期间最初接受玻璃体内注射雷珠单抗（IVR，0.25mg）或玻璃体内注射贝伐单抗（IVB，0.625mg）治疗的A-ROP婴儿。对婴儿进行复发随访。收集人口统计学和临床数据。分析复发时间、区域、类型、治疗情况、最终结构转归类型以及与复发相关的因素。
322例A-ROP婴儿中有108例纳入研究。55例接受IVR治疗，53例接受IVB治疗。接受IVR治疗的婴儿复发率更高（92.7%对52.8%，P<0.001），且复发间隔比接受IVB治疗的婴儿更早（7.7周对12.8周，P<0.001）。接受IVR治疗的婴儿复发可能性比接受IVB治疗的婴儿高约3.3倍。IVR组3例婴儿（5.9%）和IVB组5例婴儿（9.4%）视网膜完全血管化（P=0.72）。与IVR组相比，接受IVB治疗的婴儿中更多出现视网膜无血管区持续存在（PAR）的退行性变（52.8%对15.7%，P<0.001）。IVB组婴儿出现PAR退行性变的可能性高10倍。
接受IVR治疗的A-ROP婴儿复发率更高且复发更早，而接受IVB治疗的婴儿复发率更低且复发延迟，尽管出现PAR退行性变的可能性更高。
